- Home
- AGMH vs ICCC Comparison
AGMH vs ICCC Comparison
Compare AGMH & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- ICCC
- Stock Information
- Founded
- AGMH 2015
- ICCC 1982
- Country
- AGMH Hong Kong
- ICCC United States
- Employees
- AGMH N/A
- ICCC N/A
- Industry
- AGMH EDP Services
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- ICCC Health Care
- Exchange
- AGMH Nasdaq
- ICCC Nasdaq
- Market Cap
- AGMH 42.4M
- ICCC 45.9M
- IPO Year
- AGMH 2018
- ICCC 1987
- Fundamental
- Price
- AGMH $1.28
- ICCC $5.50
- Analyst Decision
- AGMH
- ICCC
- Analyst Count
- AGMH 0
- ICCC 0
- Target Price
- AGMH N/A
- ICCC N/A
- AVG Volume (30 Days)
- AGMH 114.2K
- ICCC 10.0K
- Earning Date
- AGMH 01-28-2025
- ICCC 02-25-2025
- Dividend Yield
- AGMH N/A
- ICCC N/A
- EPS Growth
- AGMH N/A
- ICCC N/A
- EPS
- AGMH N/A
- ICCC N/A
- Revenue
- AGMH $64,998,081.00
- ICCC $23,838,001.00
- Revenue This Year
- AGMH N/A
- ICCC N/A
- Revenue Next Year
- AGMH N/A
- ICCC N/A
- P/E Ratio
- AGMH N/A
- ICCC N/A
- Revenue Growth
- AGMH N/A
- ICCC 46.37
- 52 Week Low
- AGMH $0.47
- ICCC $3.34
- 52 Week High
- AGMH $2.20
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- AGMH 38.42
- ICCC 62.66
- Support Level
- AGMH $1.22
- ICCC $4.86
- Resistance Level
- AGMH $1.42
- ICCC $5.50
- Average True Range (ATR)
- AGMH 0.11
- ICCC 0.35
- MACD
- AGMH -0.01
- ICCC -0.01
- Stochastic Oscillator
- AGMH 23.98
- ICCC 100.00
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.